A <i>CD2AP</i> Mutation Associated with Focal Segmental Glomerulosclerosis in Young Adulthood

D Tsvetkov, Michael Hohmann, Yoland Marie Anistan, Marwan Mannaa, Christian Harteneck, Birgit Rudolph, Maik Gollasch

Clinical Medicine Insights Case Reports · 2016 · 19 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Mutations in CD2-associated protein (CD2AP) have been identified in patients with focal segmental glomerulosclerosis (FSGS); however, reports of CD2AP mutations remain scarce. We performed Sanger sequencing in a patient with steroid-resistant FSGS and identified a heterozygous CD2AP mutation (p.T374A, c.1120 A > G). Our patient displayed mild cognitive decline, a phenotypic characteristic not previously associated with CD2AP-associated FSGS. His proteinuria was remarkably reduced by treatment with cyclosporine A. Our findings expand the genetic spectrum of CD2AP-associated disorders and broaden the associated phenotype with the co-occurrence of cognitive decline. Our case shows that cyclosporin A is a treatment option for CD2AP-associated nephropathy.

References

13